Laboratory Billing Specialists
Lab & Pathology Billing - Stop Leaving Tested Revenue Behind
Maximize your laboratory revenue with specialized billing expertise. Our coders understand the complexities of clinical lab, molecular diagnostics, toxicology, and pathology billing with expert panel bundling and compliance knowledge.
Avoidable Pitfalls in Laboratory Billing
Laboratories and pathology groups face unique billing complexities that can significantly impact revenue and compliance.
Bundled Panels Are Erasing Tests You Actually Ran
Lab panels bundle together in specific ways depending on which components you ran and which payer you're billing. Get the bundling rules wrong and legitimate, separately performed tests disappear into a denied claim.
Impact: Improper bundling drives up claim denial rates
A Missing Medical-Necessity Box Can Turn Into a Fraud Audit
National and Local Coverage Determinations set strict medical-necessity rules that vary by test and by payer. Miss one and you're not just facing a denial - you're facing the kind of documentation gap that triggers a compliance audit.
Impact: Non-compliance results in denials and potential fraud audits
High-Complexity Testing Sits in Prior-Auth Limbo Longer Than You'd Expect
Molecular and genetic tests carry some of the most demanding prior-authorization requirements in lab billing, each requiring detailed clinical documentation before it's even submitted. That paperwork burden is exactly where payment gets stuck.
Impact: Authorization delays cause real payment delays
Toxicology Testing Gets Extra Scrutiny - and Extra Denials
Toxicology billing draws more payer scrutiny than almost any other lab category, with specific limitations on frequency and documentation. Without lab-specific expertise, that scrutiny turns into denials.
Impact: Toxicology denials run high without specialized expertise
Pathology Reads Get Paid Less When the Components Aren't Split Correctly
Surgical pathology and cytology interpretation involve a technical component and a professional component that have to be billed separately and correctly. Collapse them together and you're leaving part of the reimbursement on the table.
Impact: Incorrect component billing reduces reimbursement
Manual Order Entry Is Where Lab Errors Actually Start
Electronic orders, accession numbers, and result reporting move across multiple systems before a claim is ever generated. Every manual touchpoint in that chain is a chance for an error that shows up later as a denial.
Impact: Manual processes increase errors and processing time
How We Tighten Laboratory Claims
Fintax RCM assigns coders with direct laboratory experience to your account. No generalists, no learning curve - just immediate billing accuracy and revenue gains.
Lab Billing Done Carefully
With laboratory and pathology specialists on your claims, each panel, specimen, and interpretation goes out correctly the first time - so more of what you run actually gets paid.
- Panels and separate specimens captured at their full value
- Fewer denials from bundling and component errors
- Coverage rules tracked so appropriate tests aren't rejected
- Faster, cleaner payment on the work your lab already did
Medical-Necessity Review That Protects You From Audits
We check test orders against payer coverage rules before the claim goes out, so appropriate testing gets paid and the documentation gaps that trigger audits never open.
- Orders matched to the diagnoses that support payment
- Patient financial-responsibility paperwork handled when required
- Lower audit exposure on high-scrutiny testing
- Fewer write-offs from preventable necessity denials
Prior Authorization for Genetic and Molecular Testing
We clear high-complexity genetic and molecular tests before you run them, with the clinical justification payers actually require submitted upfront.
- Approvals secured before expensive tests are performed
- Clinical documentation prepared and submitted for you
- Every request tracked so nothing stalls unnoticed
- Higher approval rates and fewer costly reruns
Order-to-Claim Accuracy
We connect your lab systems so orders, specimens, and results flow into clean claims without the manual re-entry where errors start.
- Less manual data entry and fewer downstream denials
- Specimens tracked from accession through billing
- Claims generated cleanly from your existing systems
- A clear view of where each claim stands
Managed Laboratory Payment Follow-Up
Specialty-tuned billing solutions tailored specifically for clinical labs, molecular diagnostics, and pathology services.
Clinical Laboratory Billing
Expert billing for routine and specialized clinical lab tests including chemistry, hematology, and microbiology.
Chemistry panel billing / Hematology testing / Microbiology cultures / Immunology assays
Molecular Diagnostics
Specialized billing for molecular testing including genetic panels, PCR, and next-generation sequencing.
Genetic panel billing / PCR testing / NGS procedures / Oncology molecular testing
Toxicology Billing
Compliant billing for drug testing and toxicology screening with proper documentation and limitations.
Drug screening / Confirmation testing / Therapeutic drug monitoring / Pain management testing
Pathology Services
Complete billing for surgical pathology, cytology, and anatomic pathology services.
Surgical pathology / Cytology interpretation / Immunohistochemistry / Flow cytometry
What Drives Laboratory & Pathology Billing
01Why Anatomic and Clinical Work Get Paid Differently
Laboratories and pathology groups earn revenue in two very different ways, and the money leaks when they're treated the same. Anatomic pathology - the pathologist reading slides and specimens - is paid partly for the physician's interpretation and partly for the technical work of preparing the specimen, and those two halves have to be billed correctly, especially when your pathologist reads slides prepared by an outside lab.
Clinical testing of blood, fluids, and cultures is paid off a separate fee schedule entirely. A frequent source of lost anatomic revenue is collapsing multiple distinct specimens into one charge: when several separate specimens come from the same patient on the same day, each one is its own billable service at its own level of complexity, and each added stain a pathologist applies is separately payable when it's documented individually. Bill it as one lump and the practice quietly gives away the reads it actually performed.
02Cytology and Fine-Needle Aspiration: Two Bills, Not One
Fine-needle aspiration is one of the easiest places for a lab to lose money, because two different providers are usually owed for one patient encounter. The clinician who performs the aspiration is paid for the procedure itself, while the pathologist is separately paid for evaluating what was collected - and when the pathologist is physically present to confirm on the spot that the sample is adequate, that on-site assessment is its own billable service.
If your pathologist provides that on-site read but it never reaches the claim, you're giving away work that was already done at the bedside. Pap and related screening work carries its own trap: the amount you're paid depends on how the sample was collected and prepared, and when additional screening is run on the same sample it needs its own supporting reason on the order, or the payer strips it off.
03Genetic and Molecular Testing: Get Approval Before You Run It
Genetic and molecular testing is the highest-dollar, highest-risk work most labs do, and it's where cash disappears fastest when the front-end paperwork isn't handled. Many commercial payers require prior authorization for genetic panels and genomic profiling before the test is performed, with clinical justification submitted upfront - run the test first and hope for payment later, and you're gambling thousands of dollars per case on an approval you may never get.
In Medicare jurisdictions that use the MolDX program, many molecular tests must be registered before they can be paid, and proprietary lab-developed tests are covered on a payer-by-payer basis. The labs that get paid for this work treat authorization and coverage verification as a gate the specimen passes through before testing, not a problem to sort out after the result is already reported.
04The Requisition Decides Whether You Get Paid
In lab billing, the diagnosis on the requisition matters as much as the test result. Payers publish coverage rules, and Medicare formalizes them through national and local coverage determinations, that spell out which diagnoses justify which tests. The lab doesn't control that diagnosis; the ordering provider writes it, and if it doesn't meet the coverage criteria for the test ordered, the claim is denied even when the testing was clinically appropriate.
The lab ran the work and the lab eats the loss. The answer isn't calling every ordering office to argue about diagnoses. It's checking each requisition against the applicable coverage rules before the specimen is run, so a mismatch gets resolved while there's still time: the ordering provider clarifies the diagnosis, or the patient signs the notice accepting financial responsibility.
That notice only protects you if it's signed before testing; a form obtained after the fact is worthless, and for referred specimens the patient isn't even in your building, which is why the check has to happen at accessioning, not at billing.
05Small Errors, Multiplied by Thousands of Claims
A physician office that misbills one visit loses one visit's worth of revenue and usually notices. A lab that misbills one test type loses a few dollars per claim and rarely notices, because the same error rides silently on hundreds of claims a day, week after week. At lab volumes, a per-claim leak too small to flag individually adds up to a material share of annual collections.
Medicare's lab fee schedule is based on the private-payer rates labs report, and many commercial plans benchmark their own rates to it. Cuts were frozen for 2026, and new rates based on 2026 reporting take effect in 2027. Either way, billing accuracy is one of the few levers a lab controls. The practical response is denial and underpayment analysis by test category rather than by individual claim, so a systematic pattern surfaces as a pattern and gets fixed at the root instead of appealed one claim at a time.
06Referred Specimens: Who Bills Whom Matters as Much as the Test
When specimens arrive from physician offices, hospitals, or other labs, the billing arrangement determines both your margin and your legal exposure. Bill the patient's insurance directly and you keep the full contracted rate but absorb all denial risk. Invoice the referring practice instead, and it bills the payer; you get guaranteed payment with no denial risk, but at a negotiated rate that's typically lower.
In pathology, the work often splits, with the lab billing for the technical preparation while the physician bills for the interpretation, and the two sides have to coordinate or both claims deny as duplicates. The pricing trap is real: if fee-schedule cuts have lowered what payers reimburse but your client contracts haven't been renegotiated, you can end up performing referred testing below cost.
The compliance trap is worse, because federal anti-kickback and self-referral law restricts financial arrangements between labs and referring providers, and below-cost pricing structured to attract referrals invites fraud scrutiny. Each arrangement needs deliberate pricing review and documentation.
The Payer Side of Laboratory & Pathology Reimbursement
What it takes to get paid varies sharply by payer - from Medicare's fee schedules and medical-necessity rules to commercial preferred-lab networks and prior-authorization requirements on genetic and molecular testing.
- Clinical testing and pathology reads are paid off different fee schedules - billing the wrong one leaves money behind
- For tests ordered without a diagnosis Medicare recognizes, the right patient paperwork up front keeps the lab from eating the cost
- When your pathologist reads slides, the interpretation is billed separately from the technical preparation - capture both
- In MACs that use the MolDX program, many molecular tests must be registered before they can be paid
- Medicare's lab fee schedule is based on private-payer rates labs report; cuts were frozen for 2026, and new rates based on 2026 reporting take effect in 2027
- Patient financial-responsibility notices only protect the lab when signed before the test is run; a form collected afterward is invalid
- Medicaid pays for lab work at rates that vary widely by state and often sit well below Medicare - know your margins before accepting volume
- Some states route lab benefits through managed-care plans with their own rules, so requirements have to be verified per plan
- Referred lab work requires confirming the ordering provider is properly enrolled, or the claim is denied
- Genetic and high-cost panels frequently need approval first - secure it before running the test, not after
- Many plans only pay in-network labs - confirm participation before accepting the specimen or the whole claim is lost
- Some plans steer volume to preferred lab networks that pay more, so knowing where you stand affects real revenue
- Follow-on testing triggered automatically by a first result often needs notice or approval, or the payer strips it off
- Genetic and molecular testing frequently runs through a separate benefit manager for approval - plan for that step upfront
- Keep clean specimen records - ordering provider, collection date, and result delivery - because incomplete records sink otherwise-payable claims
- Confirm every ordering provider is properly enrolled with the payer, since claims get denied for orders from non-enrolled providers
- Watch filing deadlines closely - specimen processing time eats into the window, and a missed deadline is a permanent loss
- Connect your lab systems to billing so orders flow into clean claims without the manual re-entry where errors start
- Track denials and underpayments by test category, not just claim count, so a small systematic error surfaces before it compounds across months of volume
- Price client-billing arrangements deliberately and review them when payer rates change, since referral pricing carries federal compliance rules as well as margin risk
Boost Your Lab Revenue - Free Laboratory Billing Analysis
Book a Free ConsultationFrequently Asked Questions About Laboratory & Pathology Billing
Expert answers to common questions about laboratory & pathology billing, coding, insurance requirements, and revenue cycle management.
it's high-volume and low-dollar - labs process hundreds to thousands of claims a day
every test needs a diagnosis that meets the specific national or local coverage criteria for that test
billing a full panel versus its individual components changes what is paid;
Medicare's lab fee schedule is based on the private-payer rates labs report - cuts were frozen for 2026
labs must obtain advance beneficiary notices before non-covered tests or absorb the cost; and
reference labs have to manage both patient/payer billing and client (physician-office) billing for referred specimens.
At lab volumes
Specimen-based billing - pathology is billed per specimen
Technical and professional components - surgical pathology can be split into the technical (equipment/lab) and professional (interpretation) components depending on where the service is performed
Specimen-level assignment - each specimen must be assigned to the correct complexity level based on the tissue type
Special stains and immunohistochemistry - these are add-on services billed per stain or per antibody
Molecular pathology - molecular testing carries rapidly evolving codes and coverage criteria
Cytopathology - Pap-smear billing differs for manual vs automated screening and for physician interpretation
Consultation services - pathology consultations with slide review have their own coding.
The core risk is leaving revenue on the table by under-leveling specimens or missing add-on stains.
Top laboratory denials: Medical Necessity: a leading cause of lab denials - the diagnosis on the requisition does not match the payer's coverage criteria for the ordered test.
Prevention: diagnosis-to-test checks before the test is performed.
Panel Bundling: Individual components billed when a single panel applies, or a panel billed when not all its components were performed.
ABN Missing: A non-covered test performed without obtaining an Advance Beneficiary Notice - the lab absorbs the cost and can't bill the patient.
Molecular Test Authorization: Genetic and molecular tests denied for missing prior authorization, narrow coverage policies, or insufficient documentation.
Duplicate Testing: The same test billed twice on the same date of service, or repeat testing within payer frequency limits.
Distinct-Test and Waived-Test Flags: Missing the documentation that identifies genuinely separate tests, or the flag for CLIA-waived point-of-care tests.
Top pathology denials: Specimen Level Errors: Billing at the wrong specimen-complexity level - upcoding a simple skin biopsy to a higher level, or downcoding a needle biopsy that warrants a higher one. IHC Medical Necessity: Immunohistochemistry denied without a documented clinical indication - the record must show how the results will change the diagnosis or treatment. Molecular Test Coverage: Molecular pathology denied under narrow coverage policies - verify coverage before performing expensive molecular testing. Duplicate Specimens: Billing multiple specimens for fragments from the same anatomic site that should be accessioned as one. Consultation Billing: Intradepartmental consultation denied when the referring and consulting pathologist are in the same group practice. Cytopathology Method: Billing a liquid-based Pap when a conventional Pap was performed, or billing physician interpretation when automated screening was used.
Medical necessity validation - ordering tests without qualifying diagnoses is a central lab compliance issue; check diagnoses against tests before performing them
Panel unbundling - breaking apart complete panels into individual components to increase reimbursement constitutes fraud
Reflexive testing - automatically performing additional tests without a physician order or standing order protocol violates medical necessity rules
Kickback arrangements - providing free specimen collection supplies
Self-referral (Stark Law) - physician ownership in clinical labs must meet specific exceptions
ABN compliance - performing non-covered tests without ABNs and then billing patients creates financial liability for the lab
Specimen integrity - billing for results from specimens that do not meet collection or handling standards compromises both quality and compliance.
Still Have Questions?
Our team is ready to answer your specific questions and provide personalized guidance for your practice.
Rethink Laboratory Claims
Talk to a laboratory billing specialist who understands your payer mix, your billing challenges, and your revenue goals. The consultation is free and takes less than 30 minutes.